DCM
ABBV icon

Deuterium Capital Management’s AbbVie ABBV Stock Holding History

Deuterium Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-900
Closed -$1.11M – 98
2023
Q1 		$1.11M Hold
900
– – 1.74% 20
2022
Q4 		$1.67M Buy
+900
New +$138K 4.41% 5
2022
Q3 		– Sell
-760
Closed -$1.3M – 34
2022
Q2 		$1.3M Buy
+760
New +$116K 4.4% 5

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deuterium Capital Management's ABBV Position: Q1 2023 in Review

Deuterium Capital Management sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 1,984 shares — an estimated $303K sold.

Deuterium Capital Management first reported a position in ABBV in Q1 2022 and held it in 4 quarters. The position peaked at $539K in Q1 2022. 3,139 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

  • Deuterium Capital Management reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
  • Deuterium Capital Management sold 1,984 AbbVie shares in Q1 2023, an estimated $303K.
  • Deuterium Capital Management first reported a position in AbbVie in Q1 2022 and held it in 4 quarters.
  • Deuterium Capital Management's AbbVie position peaked at $539K in Q1 2022.
  • 3,139 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Deuterium Capital Management's 13F filing for Q1 2023, filed 12 May 2023.